ライフサイエンスコーパス: HTLV-1

1 HTLV-1 and HTLV-2 antibodies were measured by enzyme imm

2 HTLV-1 and HTLV-2 encode auxiliary proteins that play im

3 HTLV-1 and HTLV-2 were detected in both CD4(+) and CD8(+

4 HTLV-1 cell-to-cell transmission is dependent on the rel

5 HTLV-1 encodes a protein from the antisense strand of it

6 HTLV-1 has evolved a unique function mediated by its pos

7 HTLV-1 infection can lead to many different and often fa

8 HTLV-1 infection is endemic to Central African populatio

9 HTLV-1 infection is the etiological agent of ATL and, un

10 HTLV-1 infection of monocytes inhibited TLR3- and TLR4-i

11 HTLV-1 is a complex retrovirus that causes two distinct

12 HTLV-1 is now known to infect at least 4-10 million peop

13 HTLV-1 prevalence was 8.6% (23/269) in individuals with

14 HTLV-1 protease (HTLV-1 PR) is an aspartic protease whic

15 HTLV-1 serology was performed by Western blot on plasma

16 HTLV-1 seropositivity was associated with female sex, ol

17 HTLV-1-associated lymphoma can arise quickly in immunoco

18 HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lym

19 HTLV-1/SU2 shifted the CD4(+) T cell immortalization tro

20 HTLV-1/SU2 was capable of infecting and immortalizing fr

21 fected by human T-lymphotropic virus type 1 (HTLV-1) and can spread HTLV-1 to susceptible cells.

22 such as human T-cell leukemia virus type 1 (HTLV-1) and HIV-1.

23 Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 are closely related but pathogenicall

24 Human T-lymphotropic virus type 1 (HTLV-1) and HTLV-2 are prevalent at low levels among US

25 Human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 encode auxiliary proteins that play i

26 ith both human T-cell leukemia virus type 1 (HTLV-1) and human immunodeficiency virus type 1 (HIV-1)

27 s of human T-cell lymphotropic virus type 1 (HTLV-1) and human immunodeficiency virus type 1 (HIV-1),

28 Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviru

29 Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviru

30 against human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could b

31 ion with human T-cell leukemia virus type 1 (HTLV-1) can cause a rare form of leukemia designated adu

32 trovirus human T-cell leukemia virus type 1 (HTLV-1) contains identical DNA sequences, known as long

33 orf-I gene of human T-cell leukemia type 1 (HTLV-1) encodes p8 and p12 and has a conserved cysteine

34 Human T-cell leukemia virus type 1 (HTLV-1) establishes a lifelong infection and is linked t

35 Human T-cell leukemia virus type 1 (HTLV-1) expression depends on the concerted action of Ta

36 ple, human T-cell lymphotropic virus type 1 (HTLV-1) has been reported to infect up to 25 million peo

37 from Human T-cell Lymphotropic Virus Type 1 (HTLV-1) infection to lethal Adult T-cell Leukaemia (ATL)

38 Human T-cell leukemia virus type 1 (HTLV-1) is a complex retrovirus associated with the lymp

39 Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus, and, as such, its genome become

40 Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus that induces a fatal

41 Human T-lymphotropic virus type 1 (HTLV-1) is linked to multiple diseases, including the ne

42 cture of human T-cell leukemia virus type 1 (HTLV-1) is poorly characterized.

43 Human T-cell lymphotropic virus type 1 (HTLV-1) is the agent of HTLV-1-associated myelopathy/tro

44 Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia

45 Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia

46 Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemi

47 Human T lymphotropic virus type 1 (HTLV-1) mainly causes adult T cell leukemia and predomin

48 that the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax induces an epigenetic-dependent

49 human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p30 protein, essential for virus infectivity in

50 able for human T-cell leukemia virus type 1 (HTLV-1) particle biogenesis.

51 Human T cell leukemia virus, type 1 (HTLV-1) replication and spread are controlled by differe

52 phagy in human T-cell leukemia virus type 1 (HTLV-1) replication has, however, been uncharacterized.

53 Human T-cell lymphotropic virus type 1 (HTLV-1) screening of blood and organ donors is not manda

54 ected by human T-cell leukemia virus type 1 (HTLV-1) that recapitulate adult T-cell leukemia (ATL)-li

55 ins from human T-cell leukemia virus type 1 (HTLV-1) were resistant to the antiviral effects of all t

56 cted with Human T Lymphotropic Virus type 1 (HTLV-1) which together with existing data allows us to s

57 n, NC of human T-cell leukemia virus type 1 (HTLV-1), a deltaretrovirus, displays weaker NA binding a

58 Human T cell leukemia virus type 1 (HTLV-1), also known as human T lymphotropic virus type 1

59 Tax from human T-cell leukemia virus type 1 (HTLV-1), an etiological factor that causes adult T-cell

60 erved for human T-lymphotropic virus type 1 (HTLV-1), the first isolated human-pathogenic retrovirus.

61 Human T-cell leukemia virus type 1 (HTLV-1)-associated adult T-cell leukemia and T-cell lymp

62 Human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic parapares

63 h as human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic parapares

64 in a human T-cell lymphotropic virus type 1 (HTLV-1)-endemic area of Central Australia, and report on

65 and human T-cell lymphotropic virus type 1 (HTLV-1)-infected cells with 2-10 muM P27 caused cell mem

66 Most human T-lymphotropic virus type 1 (HTLV-1)-infected HeLa and SupT1 cells cease proliferatio

67 en in 22 human T cell leukemia virus type 1 (HTLV-1)-infected individuals by assessing their infectiv

68 0 million human T-lymphotropic virus type 1 (HTLV-1)-infected people, and many of them will develop s

69 h is human T-cell lymphotropic virus type 1 (HTLV-1).

70 and human T cell lymphotropic virus type 1 (HTLV-1).

71 SHV), and human T-lymphotropic virus type 1 (HTLV-1).

72 trovirus human T-cell leukemia virus type 1 (HTLV-1).

73 aused by human T-cell leukemia virus type 1 (HTLV-1).

74 -kappaB by the human T-lymphotropic virus 1 (HTLV-1) oncoprotein Tax immediately triggers a host sene

75 ies, including human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic parapares

76 e etiology of human T cell leukemia virus 1 (HTLV-1)-mediated adult T cell leukemia is associated wit

77 ctively), human T cell lymphotropic virus-1 (HTLV-1), and Kaposi's sarcoma herpesvirus (KSHV).

78 like the distantly related lentivirus HIV-1, HTLV-1 causes disease in only 5-10% of infected people,

79 everal regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene constitu

80 a panel of Gag proteins with chimeric HIV-1/HTLV-1 CA domains.

81 Five subjects with HAM and 2 HTLV-1 asymptomatic carriers were studied.

82 uman T cell lymphotropic virus type 1 and 2 (HTLV-1 and HTLV-2) and bovine leukaemia virus (BLV).

83 The 23 HTLV-1-positive bitten individuals reported being bitten

84 Cor pumonale (HTLV-1-positive group, 10/52; HTLV-1-negative group, 1/37; P = .023) was more frequent

85 Mother-to-child infection was excluded in 6 HTLV-1-infected bitten individuals.

86 (C. agilis in one case) were infected with a HTLV-1 subtype F strain very similar to the STLV-1 strai

87 In addition, HTLV-1-induced migration seems, in part, supported by th

88 d retained robust oncolytic activity against HTLV-1 actuated ATL cells.

89 ather moderate affinity of Indinavir against HTLV-1 PR and provides the basis for further structure-g

90 ortant aspects of the human response against HTLV-1 and could be an important tool for the developmen

91 e evaluated as privileged structures against HTLV-1 protease (HTLV-1 PR).

92 t be useful for developing a vaccine against HTLV-1.

93 raction of the brain stem was reduced in all HTLV-1-infected patients compared with controls (P < 0.0

94 oup, 1/37; P = .023) was more frequent among HTLV-1-seropositive adults, who also experienced a highe

95 An HTLV-1 transmission event caused by a multiple organ don

96 Here we report an HTLV-1 recombinant virus among infected individuals in N

97 ave used cryo-electron tomography to analyze HTLV-1 particle morphology.

98 have shown for the first time that HIV-1 and HTLV-1 Gag domains outside the CA (e.g., matrix and nucl

99 ly fundamental differences between HIV-1 and HTLV-1 Gag trafficking and membrane association.

100 cal agent of adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesi

101 ive agent of adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesi

102 Although both BLV and HTLV-1 infection are characterised by large expansions o

103 Iatrogenic transmission of HCV and HTLV-1 occurred in mid-20th century Kinshasa, at the sam

104 with concomitant inhibition of NF-kappaB and HTLV-1 long terminal repeat (LTR) activation.

105 causative agent of adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesi

106 B'-PP2A and HTLV-1 IN display nuclear co-localization, and the B' su

107 Validity of diagnostic procedures and HTLV-1 disease association in immunosuppressed organ rec

108 n the control of nuclear RNA trafficking and HTLV-1-induced latency.

109 drug target for the discovery of novel anti-HTLV-1 drugs.

110 an T-cell leukemia virus (HTLV; now known as HTLV-1) produced by a T-cell line from a lymphoma patien

111 e receptor expression did not differ between HTLV-1-infected and uninfected individuals.

112 n allowing us to understand the link between HTLV-1 HBZ and ATL in infected individuals.

113 eukemia (ATL), a T-cell malignancy caused by HTLV-1 infection.

114 malignant or inflammatory diseases caused by HTLV-1.

115 vent the senescence and G1 arrest induced by HTLV-1 Tax and vFLIP, respectively.

116 rm that hunters in Africa can be infected by HTLV-1 that is closely related to the strains circulatin

117 HOS) cell line to be chronically infected by HTLV-1.

118 ome senescent immediately after infection by HTLV-1 or transduction of the HTLV-1 tax gene.

119 rt the notion that infection of monocytes by HTLV-1 is likely a requisite for viral persistence in hu

120 in blood and biopsies of organ recipients by HTLV-1 real-time polymerase chain reaction (PCR).

121 Consistently, HTLV-1 molecular clones replicate better and produce mor

122 requirement for Rex to export Rex-dependent HTLV-1 transcripts.

123 requirement for Rex to export Rex-dependent HTLV-1 transcripts.

124 We detected HTLV-1 DNA in all three monocyte subsets and found that

125 ses, including the neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesi

126 mia (ATL)-like leukemic symptoms and display HTLV-1-specific adaptive immune responses.

127 As a first step in designing an effective HTLV-1 vaccine, we defined the CD8(+) and CD4(+) T cell

128 st defense responses, which may help explain HTLV-1-related pathogenesis and oncogenesis.

129 Higher cerebrospinal fluid HTLV-1 proviral load (p = 0.01) was associated with thin

130 Different genotypes exist for HTLV-1: Genotypes b and d to g are restricted to central

131 The risk factors for HTLV-1 acquisition in humans via the interspecies transm

132 Risk factors for HTLV-1 seropositivity included intravenous injections at

133 PCR was carried out for HTLV-1 provirus on buffy-coat DNAs.

134 ic explanation of the requirement of p30 for HTLV-1 infectivity in vivo, suggest that dampening inter

135 s have been described, such a regulation for HTLV-1 has not been reported.

136 opsy results support an etiological role for HTLV-1 in these cases of primary cutaneous T-cell lympho

137 first-time donors, 104 were seropositive for HTLV-1 (prevalence, 5.1 cases/per 100 000; 95% confidenc

138 e development of a therapeutic treatment for HTLV-1-mediated disease.

139 We hypothesized that exosomes derived from HTLV-1-infected cells contain unique host and viral prot

140 he antisense transcript-encoded protein from HTLV-1, is now well recognized as a potential factor for

141 ore, we observed that exosomes released from HTLV-1-infected Tax-expressing cells contributed to enha

142 All three monocyte subsets sorted from HTLV-1-infected individuals were positive for viral DNA,

143 role in extracellular delivery of functional HTLV-1 proteins and mRNA to recipient cells.

144 fs of five retroviruses of different genera: HTLV-1, HIV-1, murine leukaemia virus (MLV), avian sarco

145 We generated HTLV-1 envelope recombinant virus containing the HTLV-2

146 HTLV-1-associated myelopathy (HAM; HTLV-1 is human T-lymphotropic virus type 1) is a chroni

147 ins provide a better understanding about how HTLV-1 infection is associated with disease and HTLV-2 i

148 these functional differences may affect how HTLV-1 causes disease but HTLV-2 generally does not.

149 Human T-cell lymphotropic virus type I (HTLV-1) is an oncogenic retrovirus considered to be the

150 Human T-cell leukemia virus type I (HTLV-1) replication relies on the clonal expansion of it

151 The human T-cell lymphotropic virus type I (HTLV-1) Tax transactivator initiates transformation in a

152 a defined capsid core, which likely impacts HTLV-1 particle infectivity.

153 er showed that asparagine at position 195 in HTLV-1 SU is involved in determining this CD4(+) T cell

154 ion of TrkB signaling increases apoptosis in HTLV-1-infected T cells and reduces phosphorylation of g

155 ing factor for dysregulation of autophagy in HTLV-1-transformed T cells and Tax-immortalized CD4 memo

156 levels of H3K18 acetylation were detected in HTLV-1 infected cells compared to non-infected cells.

157 this effect, BDNF expression is elevated in HTLV-1-infected T-cell lines compared to uninfected T ce

158 Among several regulatory/accessory genes in HTLV-1, HTLV-1 bZIP factor (HBZ) is the only viral gene

159 contribute to determining the role of HBZ in HTLV-1-associated diseases.

160 CX3CR1 in classical monocytes were higher in HTLV-1-infected individuals than uninfected individuals;

161 Expression of TrkB is also higher in HTLV-1-infected T-cell lines than in uninfected T cells.

162 assical patrolling monocytes is increased in HTLV-1-infected individuals, and they have increased exp

163 F/TrkB autocrine/paracrine signaling loop in HTLV-1-infected T cells that enhances the survival of th

164 that is downregulated by miR17 and miR21 in HTLV-1-infected CD4(+) T cells.

165 a single amino acid substitution, N195D, in HTLV-1 SU (Ach.195) resulted in a shift to a CD8(+) T ce

166 hting the importance of the HTLV-1 CA NTD in HTLV-1 immature particle morphology.

167 hat, albeit rare, recombination can occur in HTLV-1 and may play a role in the evolution of this retr

168 similarly provoked a loss of Tax protein in HTLV-1-transformed cells.

169 demonstrate the presence of recombinants in HTLV-1.

170 igenin and chrysin break TRAIL resistance in HTLV-1-associated ATL by transcriptional down-regulation

171 ng that miR-28 may play an important role in HTLV-1 transmission.

172 ein that plays essential regulatory roles in HTLV-1 replication and oncogenic transformation of T lym

173 No effects were seen in HTLV-1-negative cell lines.

174 ell-to-cell transmission, a critical step in HTLV-1 transmission and pathogenesis.

175 ng production of infectious HIV-1 virions in HTLV-1-infected cells through the induction of APOBEC3G.

176 gosomes and that this accumulation increases HTLV-1 production.

177 s have important implications for infectious HTLV-1 spread, particularly in the context of cell-to-ce

178 this study, we found that miR-28-3p inhibits HTLV-1 virus expression and its replication by targeting

179 ata provide further mechanistic insight into HTLV-1-mediated subversion of cellular host defense resp

180 nsfected with Rex-wild-type and Rex-knockout HTLV-1 molecular clones using splice site-specific quant

181 Despite low prevalence, many HTLV-1-infected patients who do not fulfill criteria for

182 Moreover, HTLV-1 infection was linked to bite severity.

183 bination analysis approaches to a set of new HTLV-1 sequences, which we collected from 19 countries t

184 protective role of miR-28-3p against de novo HTLV-1 infection.

185 at Gag proteins with a chimeric HIV-1 CA NTD/HTLV-1 CA CTD did not result in Gag oligomerization rega

186 P patients, 4 asymptomatic carriers (ACs) of HTLV-1, 18 MS patients, and 10 HVs from a 3T magnetic re

187 the differences in transforming activity of HTLV-1 and -2.

188 tropic virus type 1 (HTLV-1) is the agent of HTLV-1-associated myelopathy/tropical spastic paraparesi

189 Analysis of HTLV-1 integrations in two cell lines, HuT 102 and MJ, i

190 lassical monocytes was lower in the blood of HTLV-1-infected individuals than in that of uninfected i

191 The brains of HTLV-1-infected patients, with and without HAM but no cl

192 controls [HCs], 17 asymptomatic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS

193 g its expression within a molecular clone of HTLV-1.

194 Functional comparisons of HTLV-1 and HTLV-2 proteins provide a better understandin

195 gy to deregulate autophagy in the context of HTLV-1 transformation of T cells.

196 to examine in depth the molecular events of HTLV-1 replication and the mechanisms of action of viral

197 ur and could play a role in the evolution of HTLV-1.

198 ase class III resulted in impaired growth of HTLV-1-transformed T cells, indicating a critical role o

199 igh prevalence might reduce the incidence of HTLV-1-induced disease.

200 evidence that the known poor infectivity of HTLV-1 particles may correlate with HTLV-1 particle popu

201 al clue to understanding the infiltration of HTLV-1-infected lymphocytes into various tissues and sug

202 ge, the most potent nonpeptidic inhibitor of HTLV-1 PR described so far.

203 2 (A3H hapII) acted as potent inhibitors of HTLV-1.

204 er with prior findings in a macaque model of HTLV-1 infection, support the notion that infection of m

205 unately, there are very few animal models of HTLV-1 infection useful for testing vaccine approaches.

206 A number of HTLV-1 subtypes have been described in different populat

207 bjective measures of gait, quantification of HTLV-1 proviral load in peripheral blood mononuclear cel

208 Replication of HTLV-1 is under the control of two major trans-acting pr

209 PA28gamma acts as a co-repressor of HTLV-1 p30 to suppress virus replication and is required

210 The X-ray structure of HTLV-1 PR in complex with the well-known and approved HI

211 Such a system can facilitate the study of HTLV-1 replication in cell culture.

212 ammatory myelopathy occurring in a subset of HTLV-1-infected individuals.

213 cl-x(L) knockdowns decreased the survival of HTLV-1-infected T-cell lines, although no cell death was

214 The p9 localization is similar to that of HTLV-1 p12 and induced a strong decrease in the calretic

215 We hypothesized that transformation of HTLV-1-infected CCR4+ T cells into Th1-like cells plays

216 Finally, treatment of HTLV-1-transformed cell lines with 17-DMAG suppressed HT

217 Treatment of HTLV-1-transformed cells with the HSP90 inhibitor 17-DMA

218 s can be used to quantify and study HIV-1 or HTLV-1 cell-mediated infection in a simple one-step tran

219 Here we demonstrate that ATL-derived or HTLV-1-transformed cells are dependent on continuous Tax

220 rative disorder tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM).

221 ia/lymphoma and tropical spastic paraparesis/HTLV-1-associated myelopathy in about 5% of infected ind

222 esent an essential early step for permissive HTLV-1 infection and persistence.

223 -expressing rat fibroblasts and Tax-positive HTLV-1-infected cells and Tax-mediated cell transformati

224 The diagnosis of potentially HTLV-1-associated disease in organ recipients may requir

225 .54; 95% CI, 1.04-70.03; P = .046) predicted HTLV-1 infection.

226 The ease with which chronic and productive HTLV-1 infection can be established in cell culture thro

227 HTLV-1 protease (HTLV-1 PR) is an aspartic protease which represents a pr

228 ivileged structures against HTLV-1 protease (HTLV-1 PR).

229 Proviral HTLV-1 DNA concentration was almost 100 copies/10(2) cel

230 Proviral HTLV-1-DNA was detected in all blood samples of 3 organ

231 Cor pumonale (HTLV-1-positive group, 10/52; HTLV-1-negative group, 1/3

232 ity is required for p30's ability to repress HTLV-1.

233 zed that A3 proteins other than A3G restrict HTLV-1.

234 As a retrovirus, HTLV-1 integrates its genome into a host cell chromosome

235 The human-pathogenic retroviruses HTLV-1 and HIV-1 can be transmitted more efficiently in

236 Since HTLV-1, much like HIV, targets CD4(+) T cells, we hypoth

237 ling the expression of alternatively spliced HTLV-1 mRNAs and suggest a link between the cycling prop

238 of the complete set of alternatively spliced HTLV-1 mRNAs.

239 otropic virus type 1 (HTLV-1) and can spread HTLV-1 to susceptible cells.

240 Stable HTLV-1-producing HOS cell clones can be readily establis

241 r B' incapable of binding to and stimulating HTLV-1 and -2 IN strand transfer activity.

242 ansformed cell lines with 17-DMAG suppressed HTLV-1 replication and promoted apoptotic cell death.

243 ory mechanism may be important for long-term HTLV-1 infection.

244 Our results demonstrate that HTLV-1 Gag is capable of membrane targeting and particle

245 Here, we demonstrate that HTLV-1 p30 recruits the cellular proteasome activator PA

246 sion electron microscopy to demonstrate that HTLV-1 particles produced from a distinct chronically in

247 chronically infected T cells, we found that HTLV-1 affects CRMP2 activity, resulting in an increased

248 Previously, our group found that HTLV-1 HBZ and HTLV-2 APH-2 had distinct effects in vivo

249 In addition, we found that HTLV-1, subtype 1A isolates corresponding to the Japanes

250 We show here that HTLV-1 may be able to successfully infect the T cells an

251 Taken together, our data indicate that HTLV-1 is a likely target for multiple A3 proteins.

252 Here, we report that HTLV-1 infection increases the accumulation of autophago

253 Importantly, we revealed that HTLV-1 bZIP factor (HBZ) protein which is expressed in a

254 Evidence suggests that HTLV-1, via the viral protein Tax, exploits CD4+ T cell

255 The HTLV-1 and HTLV-2 prevalences among US blood donors has

256 The HTLV-1 genome encodes the Tax protein that plays essenti

257 The HTLV-1 oncoprotein Tax is a potent activator of classica

258 The HTLV-1 particle structure is still poorly understood, an

259 The HTLV-1 transactivator protein Tax controls many critical

260 All the HTLV-1-positive hunters bitten by a gorilla or chimpanze

261 Here, we dissect the HTLV-1 SU further to identify key domains that are invol

262 antisense strand of its proviral genome, the HTLV-1 basic leucine zipper factor (HBZ), which inhibits

263 respectively, which, in contrast to HBZ, the HTLV-1 homologue, do not contain a typical bZIP domain.

264 Indeed, the HTLV-1 strains currently present in North Africa have or

265 To more clearly define the roles of the HTLV-1 CA amino-terminal domain (NTD) and CA CTD in part

266 articles, highlighting the importance of the HTLV-1 CA NTD in HTLV-1 immature particle morphology.

267 The surface component (SU) of the HTLV-1 envelope is responsible for binding to the cellul

268 ing experimental system for the study of the HTLV-1 particle structure.

269 r infection by HTLV-1 or transduction of the HTLV-1 tax gene.

270 CTD, but the HIV-1 CA NTD cannot replace the HTLV-1 CA CTD, indicating that the HTLV-1 CA subdomains

271 In this study, the HTLV-1 capsid amino-terminal domain was found to provide

272 observations support the conclusion that the HTLV-1 CA NTD can functionally replace the HIV-1 CA CTD,

273 place the HTLV-1 CA CTD, indicating that the HTLV-1 CA subdomains provide distinct contributions to G

274 We found that the HTLV-1 Tax protein increases cellular autophagosome accu

275 In this study, we found that the HTLV-1-encoded protein HBZ activates expression of BDNF,

276 Furthermore, chimeric Gag proteins with the HTLV-1 CA NTD produced particles phenotypically similar

277 y structures of two representatives bound to HTLV-1 PR were determined, and the structural basis of t

278 st and viral proteins that may contribute to HTLV-1-induced pathogenesis.

279 lia, and report on 53 individuals exposed to HTLV-1 with no transmissions documented (95% confidence

280 type 1 (STLV-1), a virus closely related to HTLV-1, in olive baboons (Papio anubis).

281 d in resting T cells, which are resistant to HTLV-1 infection, we investigated a potential protective

282 ttributed to the cellular immune response to HTLV-1-infected lymphocytes.

283 produced particles phenotypically similar to HTLV-1 immature particles, highlighting the importance o

284 ase in the calreticulin signal, similarly to HTLV-1 p12.

285 and Env proteins persistently; and transmit HTLV-1 to naive HOS, SupT1, and Jurkat T reporter cell l

286 In arsenic/interferon-treated HTLV-1 transformed or ATL cells, Tax is recruited onto N

287 T cell immortalization tropism of wild-type HTLV-1 (wtHTLV-1) to a CD8(+) T cell preference.

288 rus (HPV), human T-cell lymphotrophic virus (HTLV-1) and human immunodeficiency virus (HIV).

289 s (HCV) and human T-cell lymphotropic virus (HTLV-1) can be used to investigate past iatrogenic trans

290 re infected with human T lymphotropic virus (HTLV-1).

291 25.9%) were HCV seropositive; 26 (3.1%) were HTLV-1-seropositive.

292 A vaccine is urgently needed in areas where HTLV-1 is endemic.

293 These data suggest a model whereby HTLV-1 infection augments the number of classical monocy

294 r cancers and other diseases associated with HTLV-1 infection.

295 ivity of HTLV-1 particles may correlate with HTLV-1 particle populations containing few virus particl

296 ression in ATLL cells latently infected with HTLV-1 reactivates expression of viral tax/rex RNA and t

297 hocytic cell lines chronically infected with HTLV-1, particularly the MT-2 cell line, which harbors t

298 ysregulation of CD4(+) T cells infected with HTLV-1.

299 FACT proteins also interfere with HTLV-1 Tax-LTR-mediated transcription and viral latency,

300 ion and disease progression in patients with HTLV-1-associated inflammatory diseases.